Retatrutide 30mg
Innovative Triple Agonist Driving Superior Weight Reduction and Metabolic Balance.
Formula: C₂₆₇H₄₀₄N₆₄O₈₁ (Molecular Weight ~ 4957.6 g/mol)
Description
Retatrutide 30 mg is an innovative triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors all at once, offering a superior multi-pathway metabolic intervention. This multi-receptor activation elevates energy expenditure, enhances satiety, and provides unparalleled efficacy in weight reduction and glycemic control.
Mechanism of Action
GLP-1 agonism: enhances insulin secretion and satiety;
GIP agonism: potentiates glucose-dependent insulin response;
Glucagon receptor agonism: boosts energy expenditure and fat oxidation.
Clinical Applications
Severe obesity, particularly cases resistant to GLP-1 monotherapy;
Type 2 Diabetes Mellitus with complex metabolic dysfunctions;
Cardiometabolic conditions requiring simultaneous enhancement of weight loss and insulin sensitivity.
Clinical Data
Phase 2 trials demonstrated average weight loss exceeding 24% of body weight in non-diabetic obese participants, positioning Retatrutide as one of the most effective investigational peptides for obesity management.
Preclinical receptor binding assays show EC₅₀ values of ~0.0643 nM (GLP-1), 0.775 nM (GIP), and 5.79 nM (glucagon), with an estimated half-life of ~6 days.
Retatrutide 30 mg is shipped as a lyophilized sterile powder, stable at room temperature for several weeks. For longer-term storage, refrigeration at 2°C–8°C is recommended, while ultra-low freezing at –80°C preserves the peptide’s stability for several years. Once reconstituted with bacteriostatic water, retatrutide remains stable for 30 days under refrigeration.
To prevent degradation, the vial must be shielded from light, moisture, and repeated temperature fluctuations. The freeze-drying process ensures that the peptide remains chemically intact, preventing hydrolytic degradation and maintaining maximum potency until reconstitution.
Retatrutide 30 mg is a triple receptor agonist peptide with the molecular formula C₂₆₇H₄₀₄N₆₄O₈₁ and a molecular weight of ~4957.6 g/mol. Its structure allows for simultaneous activation of GLP-1, GIP, and glucagon receptors.
GLP-1 agonism: stimulates insulin release and promotes satiety.
GIP agonism: complements GLP-1 action and enhances glucose control.
Glucagon receptor agonism: increases basal metabolic rate, fat oxidation, and energy expenditure.
Its pharmacokinetic profile is characterized by an estimated half-life of 6 days, making it suitable for once-weekly dosing. Excipients include trehalose, mannitol, and polysorbate 80 for enhanced solubility, stability, and protection against aggregation.
Retatrutide 30 mg is produced through advanced peptide synthesis under ISO-certified and GMP-regulated facilities. Each lot is subjected to HPLC and LC-MS analysis to confirm amino acid sequence, structural integrity, and purity levels exceeding 99%. Endotoxin testing, sterility checks, and stability assays are performed to validate safety and compliance.
The peptide is provided as a lyophilized sterile powder for long-term preservation. Excipients such as trehalose, mannitol, and polysorbate 80 are commonly included to maintain solubility, isotonicity, and prevent aggregation. All components meet pharmacopeial specifications and undergo stringent quality control testing.
Every vial is batch-controlled with serialized traceability, ensuring full transparency in quality assurance. Manufacturing documentation, analytical certificates, and batch validation are maintained according to regulatory guidelines, reinforcing confidence in both purity and safety.
Retatrutide 30 mg is a first-in-class triple agonist, simultaneously activating GLP-1, GIP, and glucagon receptors. This unique receptor activity provides a comprehensive metabolic intervention:
GLP-1 agonism: promotes satiety, reduces food intake, and enhances glucose-dependent insulin secretion.
GIP agonism: synergistically augments insulin release and complements GLP-1 actions.
Glucagon receptor agonism: increases basal energy expenditure and fat oxidation, supporting enhanced weight reduction.
Pharmacological studies reveal that Retatrutide has EC₅₀ values of 0.0643 nM (GLP-1), 0.775 nM (GIP), and 5.79 nM (glucagon), demonstrating strong potency across multiple pathways. Its estimated half-life of ~6 days supports convenient weekly dosing.
In Phase 2 trials, non-diabetic obese participants achieved an average body weight reduction exceeding 24%, setting a new benchmark in metabolic therapies. Adverse events were primarily mild gastrointestinal symptoms, consistent with other incretin-based therapies.
